Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)

Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care. The soluble guanylate cyclase stimulator riociguat is licensed for the treatment of pulmonary arterial hypertension; here we present...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pulm Circ
Autors principals: Ghofrani, Hossein-Ardeschir, Grünig, Ekkehard, Jansa, Pavel, Langleben, David, Rosenkranz, Stephan, Preston, Ioana R., Rahaghi, Franck, Sood, Namita, Busse, Dennis, Meier, Christian, Humbert, Marc
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7366414/
https://ncbi.nlm.nih.gov/pubmed/32728421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045894020942121
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars